Minimally symptomatic posterior reversible encephalopathy in Guillain-Barré syndrome.

Posterior reversible encephalopathy syndrome (PRES) is a rare occurrence in patients with Guillain-Barré syndrome (GBS). Two patients with neuroradiological evidence of PRES without central nervous system (CNS) symptoms were recently reported. We present the case of a GBS patient with minimal CNS symptoms and magnetic resonance imaging findings consistent with PRES.

Reversible cerebral vasoconstriction syndrome possibly induced by etoricoxib.

Etoricoxib is a newer cyclooxygenase (COX)-2 inhibitor anti-inflammatory drug with a favorable safety profile. However, several randomized trials have provided evidence of an increased risk for acute myocardial infarction associated with the use of COX-2 inhibitors. Fewer data are available concerning the risk for ischemic stroke associated with COX-2 inhibitors.

Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.

Background: Thrombolysis with rt-PA is the only approved pharmacological therapy for acute ischemic stroke presently administrable in a 3-hour window (very recently extended to 4.5 h). After this time, the choice is limited to endovascular treatment and antiplatelet drugs, mainly aspirin (ASA), the efficacy of which in the acute phase of stroke has poorly been evaluated.

Ataxic hemiparesis syndrome clinical and CT study of 20 new cases.

Twenty patients suffering from ataxic hemiparesis caused by lacunar infarcts were studied using computerized tomography. Supratentorial lesions were found in nineteen patients (95%) while subtentorial lesion was found in only one patient (5%). In all cases the lesions were localized along the corticopontine pathways, making the hypothesis of injury to this pathway the most valid explanation of ataxia.